Pediatric cancer patients vaccinated against SARS-CoV-2-a clinical and laboratory follow-up
© 2024. The Author(s)..
BACKGROUND: Vaccination against SARS-CoV-2 is recommended for cancer patients. However, long-term data on the effectiveness in the pediatric setting are lacking.
METHODS: Pediatric patients < 18 years on active treatment for cancer and without prior SARS-CoV-2 infection received three doses of an mRNA vaccine. The clinical course and humoral and cellular immunity were evaluated at the end of the follow-up period of ≥ 1 year after the third dose of vaccine.
RESULTS: SARS-CoV-2 infection occurred in 17 of 19 analyzed patients (median age 16.5 years) during the follow-up period (median 17 months), but no severe symptoms were seen. At ≥ 1 year after the last SARS-CoV-2 antigen exposure, 4 of 17 patients had received the recommended booster vaccine. At the end of the follow-up period, all evaluable 15 patients had anti-SARS-CoV-2 receptor-binding domain IgG antibodies. Twelve of the 15 patients had neutralizing antibody titers ≥ 1:10 against the Delta variant and 12/15 and 13/15 against the BA.1 and BA.5 variants, respectively. Specific T cells against SARS-CoV-2 antigens were seen in 9/13 patients.
CONCLUSIONS: Most SARS-CoV-2-vaccinated pediatric cancer patients had SARS-CoV-2 infections and limited interest in booster vaccination. At 1 year after the last antigen exposure, which was mostly an infection, humoral immune responses remained strong.
TRIAL REGISTRATION: German Clinical Trials Register DRKS00025254, May 26, 2021.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:32 |
|---|---|
| Enthalten in: |
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer - 32(2024), 4 vom: 11. März, Seite 221 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Siebald, Benjamin [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Viral |
|---|
| Anmerkungen: |
Date Completed 13.03.2024 Date Revised 17.04.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00520-024-08422-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369575547 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369575547 | ||
| 003 | DE-627 | ||
| 005 | 20240417232621.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240312s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00520-024-08422-5 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1378.xml |
| 035 | |a (DE-627)NLM369575547 | ||
| 035 | |a (NLM)38467829 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Siebald, Benjamin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pediatric cancer patients vaccinated against SARS-CoV-2-a clinical and laboratory follow-up |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.03.2024 | ||
| 500 | |a Date Revised 17.04.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a BACKGROUND: Vaccination against SARS-CoV-2 is recommended for cancer patients. However, long-term data on the effectiveness in the pediatric setting are lacking | ||
| 520 | |a METHODS: Pediatric patients < 18 years on active treatment for cancer and without prior SARS-CoV-2 infection received three doses of an mRNA vaccine. The clinical course and humoral and cellular immunity were evaluated at the end of the follow-up period of ≥ 1 year after the third dose of vaccine | ||
| 520 | |a RESULTS: SARS-CoV-2 infection occurred in 17 of 19 analyzed patients (median age 16.5 years) during the follow-up period (median 17 months), but no severe symptoms were seen. At ≥ 1 year after the last SARS-CoV-2 antigen exposure, 4 of 17 patients had received the recommended booster vaccine. At the end of the follow-up period, all evaluable 15 patients had anti-SARS-CoV-2 receptor-binding domain IgG antibodies. Twelve of the 15 patients had neutralizing antibody titers ≥ 1:10 against the Delta variant and 12/15 and 13/15 against the BA.1 and BA.5 variants, respectively. Specific T cells against SARS-CoV-2 antigens were seen in 9/13 patients | ||
| 520 | |a CONCLUSIONS: Most SARS-CoV-2-vaccinated pediatric cancer patients had SARS-CoV-2 infections and limited interest in booster vaccination. At 1 year after the last antigen exposure, which was mostly an infection, humoral immune responses remained strong | ||
| 520 | |a TRIAL REGISTRATION: German Clinical Trials Register DRKS00025254, May 26, 2021 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cancer | |
| 650 | 4 | |a Follow-up | |
| 650 | 4 | |a Immunocompromised | |
| 650 | 4 | |a Pediatrics | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Vaccination | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Vaccines |2 NLM | |
| 700 | 1 | |a Groll, Andreas H |e verfasserin |4 aut | |
| 700 | 1 | |a Salou, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Boldt, Andreas |e verfasserin |4 aut | |
| 700 | 1 | |a Seiffert, Sabine |e verfasserin |4 aut | |
| 700 | 1 | |a Sack, Ulrich |e verfasserin |4 aut | |
| 700 | 1 | |a Reemtsma, Judith |e verfasserin |4 aut | |
| 700 | 1 | |a Jassoy, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Klusmann, Jan-Henning |e verfasserin |4 aut | |
| 700 | 1 | |a Ciesek, Sandra |e verfasserin |4 aut | |
| 700 | 1 | |a Hoehl, Sebastian |e verfasserin |4 aut | |
| 700 | 1 | |a Lehrnbecher, Thomas |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer |d 1994 |g 32(2024), 4 vom: 11. März, Seite 221 |w (DE-627)NLM07487618X |x 1433-7339 |7 nnns |
| 773 | 1 | 8 | |g volume:32 |g year:2024 |g number:4 |g day:11 |g month:03 |g pages:221 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00520-024-08422-5 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 32 |j 2024 |e 4 |b 11 |c 03 |h 221 | ||